nonalcoholic%20fatty%20liver%20disease
NONALCOHOLIC FATTY LIVER DISEASE

Nonalcoholic fatty liver disease is having excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes.

It is considered as a hepatic manifestation of metabolic syndrome.

Progression of nonalcoholic fatty liver disease is variable.

Introduction

  • Fatty liver is usually an incidental finding on abdominal imaging that reveals hepatic steatosis and laboratory study results of elevated liver enzymes
  • Considered as hepatic manifestation of metabolic syndrome (obesity, type 2 diabetes mellitus, insulin resistance, dyslipidemia and hypertension)
  • Most common liver disorder in the Western countries but less commonly reported in its general population
  • Becoming a serious health issue in many Asian countries
  • Prevalence is 2x higher in males than in females
  • Progression of nonalcoholic fatty liver disease (NAFLD) is variable; ranges from hepatic steatosis through inflammatory nonalcoholic steatohepatitis (NASH) to fibrosis or cirrhosis
  • Major cause of mortality in patients with NAFLD is cardiovascular disease

Definition

  • Excessive hepatic fat (in the form of triglycerides) accumulation not due to excessive alcohol consumption or other secondary causes

Signs and Symptoms

  • Patient usually presents asymptomatic but may describe vague right upper quadrant pain, fatigue and malaise

Risk Factors

  • Obesity
  • Insulin resistance/metabolic syndrome
  • High-calorie diet with saturated fats, refined carbohydrates, sugar-sweetened beverages and high fructose
  • Jejunoileal bypass surgery
  • Highest risk in 40-65 years old
  • Higher risk in Hispanics and Asians while lower risk in African-Americans
  • Genetic predisposition
  • Drugs and toxins (eg Amiodarone, Coralgil, corticosteroids, synthetic estrogens, Methotrexate, IV Tetracycline)
  • Polycystic ovary syndrome 
  • Hypothyroidism
  • Obstructive sleep apnea 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.